Clinical Trials in Baltimore

Showing 15161-15180 of 23,476 trials

Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer

NCT00711997

This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of DTA-H19 administered intratumorally in patients with unresectable, locally advanced pancreatic cancer. Primary Objective: The primary objective is to determine the maximum tolerated dose (MTD) of intratumoral DTA-H19 and identify any dose limiting toxicities (DLTs). Secondary objectives include determining the adverse events (AEs) profile, effects on clinical laboratory analytes, vital signs, PK, tumor response, and possible tumor resectability after 4 intratumoral administrations of DTA-H19.

Pancreatic Neoplasms

Anchiano Therapeutics Israel Ltd.9 participantsStarted Aug 2009

Baltimore, Maryland, United States • Jerusalem, Israel • Kfar Saba, Israel +1 more locations

UNKNOWNPhase 2< 1 mile

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

NCT03205345

This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new decompensation events, and MELD score progression are events) in subjects with decompensated NASH cirrhosis.

Decompensated Cirrhosis

Conatus Pharmaceuticals Inc.210 participantsStarted Jun 2017

Chandler, Arizona, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +73 more locations

Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

Find Trials by Condition in Baltimore

Cell-Based Approaches For Modeling and Treating Ataxia-Telangiectasia

Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults

Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation

Moderate Alcohol and Cardiovascular Health Trial

Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Pilot Project to Evaluate the Revolutionizing Prosthetics Modular Prosthetic Limb System for Upper Extremity Amputees

Effect of Dietary Cholesterol on Plasma Lipids

A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

52-104 Week Off-therapy Second Extension to Study CSPP100A2365

UltraShape Power for Abdominal Fat and Circumference Reduction

A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years